Shopping Cart 0
Cart Subtotal
AED 0

KOL Perspectives: Patient Niches in IBD

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 27525

Details

KOL Perspectives: Patient Niches in IBD

Summary

This KOL Insight briefing focuses on KOLs views of Patient Niches in IBD.

Questions topics-

- Perceptions on patient niches and treatments of fistulizing Crohn's disease

- Perceptions on patient niches and treatments in small-bowel Crohn's disease

- Perceptions on patient niches and treatments in pouchitis

- Perceptions on patient niches and treatments in acute severe UC

Key Highlights

- Most KOLs were unsure of the efficacy profile for JAK inhibitors in the treatment of fistulizing Crohn's disease

- Most KOLs flagged the need for a targeted therapy that prevents long-term complications of SBCD

- Most KOLs noted that up to 50% of UC patients experience pouchitis after surgery, with antibiotics typically used before biologics.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our IBD key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during July 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on Patient Niches in IBD

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

IBD, fistulizing, small bowel, pouchitis


Companies

Janssen

Takeda

AbbVie

Gilead

Atlantic

Company Profile

Company Profile Title

KOL Perspectives: Patient Niches in IBD

Summary

This KOL Insight briefing focuses on KOLs views of Patient Niches in IBD.

Questions topics-

- Perceptions on patient niches and treatments of fistulizing Crohn's disease

- Perceptions on patient niches and treatments in small-bowel Crohn's disease

- Perceptions on patient niches and treatments in pouchitis

- Perceptions on patient niches and treatments in acute severe UC

Key Highlights

- Most KOLs were unsure of the efficacy profile for JAK inhibitors in the treatment of fistulizing Crohn's disease

- Most KOLs flagged the need for a targeted therapy that prevents long-term complications of SBCD

- Most KOLs noted that up to 50% of UC patients experience pouchitis after surgery, with antibiotics typically used before biologics.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our IBD key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during July 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on Patient Niches in IBD

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

IBD, fistulizing, small bowel, pouchitis


Companies

Janssen

Takeda

AbbVie

Gilead

Atlantic